Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Crispr Therapeutics AG (CRSP) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance

Crispr Therapeutics AGTrade
YieldMax Magnificent 7 Fund of Option Income ETFsTrade

Price performance (Past 24H)

Key statistics

Crispr Therapeutics AG vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? Crispr Therapeutics AG trades at $53.95 (market cap $5.23B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.31. The key difference: Crispr Therapeutics AG is trading nearer its 52-week high, YieldMax Magnificent 7 Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.

CRSPYMAG
Market Cap
$5.23B
Sector
HealthIncome / Options Overlay
52-Week High
$76.78$15.98
52-Week Low
$44.34$10.76
Enterprise Value
$3.65B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Crispr Therapeutics AG

CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.

Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.

YieldMax Magnificent 7 Fund of Option Income ETFs

YMAG trades at $11.29, down 2.59% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF generates weekly dividends, with recent payouts ranging from $0.07 to $0.40, highlighting its income-focused strategy. News coverage emphasizes distribution announcements and NAV stability concerns amid earnings volatility.

Outlook hinges on sustained option income generation, but risks include NAV decay from call spreads and market volatility. Analyst sentiment is mixed, with some viewing it as a tactical buy in rangebound markets. Key risks are earnings-driven NAV swings and competitive ETF structures.

Returns comparison

Trailing returns across standard periods

About Crispr Therapeutics AG

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

Read more on CRSP

About YieldMax Magnificent 7 Fund of Option Income ETFs

YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.

Read more on YMAG